Safety assessments
treatment-emergent adverse events
SECONDARY
The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs), collected from all participants up to 6 months post treatment initiation. Safety data collected up to the 12 month follow-up visit were assessed as a secondary safety endpoint. Throughout the study, all repeat-dose participants recorded daily insulin use in an electronic diary.